Clinical Trials Browser

Completed × Biliary Tract Neoplasms × Head & Neck × Clear all

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Salivary Gland Neoplasms, Sarcoma, Thyroid Neoplasms, Colorectal Neoplasms

NCT05253053 2025-06-12

To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Phase 1/2 Completed

84 enrolled

BreastGastrointestinalGenitourinaryHead & NeckThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Gallbladder Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Phase 2 Completed

206 enrolled 40 charts 2 FDA

CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT01938612 2021-03-12

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

Phase 1 Completed

269 enrolled

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms

Clinical Trials

NAVIGATE

To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours